Completed PHASE1 INTERVENTIONAL 2-arm NCT02596100

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Sponsor: Portola Pharmaceuticals

Conditions Healthy

Interventions Betrixaban

Updated 9 times since 2017 Last updated: Aug 7, 2023 Started: Sep 30, 2015 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02596100, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Portola Pharmaceuticals, it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2023 — Jul 2024 [monthly]

Completed PHASE1
Sep 2023 — Dec 2023 [monthly]

Completed PHASE1
Jan 2021 — Sep 2023 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Oct 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Oct 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Portola Pharmaceuticals

Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.